Cerora CEO, Adam J. Simon, PhD announced today that his company will receive regional economic development funding from the prestigious Ben Franklin Technology Partners of Northeastern Pennsylvania. The $150,000 investment is earmarked for the development and commercialization of Cerora’s new Qumpass™ neuropsychological evaluation software and its investigational MindReader™ portable brainwave biosensor device—both for use by healthcare and sports medicine professionals in “near the field” concussion assessments and management.
“Cerora is honored to receive a second major investment by Ben Franklin and considers this funding to be an affirmation of our progress in refining our concussion technologies and readying them for the marketplace,” commented Dr. Simon. “Ben Franklin has provided us with facilities, business counsel, and financial support that have helped make it possible this year to launch Qumpass, our first commercial software product. And, with their help, near the beginning of 2015 we hope to submit MindReader, our portable brainwave sensor and software, for regulatory clearance.”
The beta version of Cerora’s Qumpass software has now been displayed at 5 major national and international neurology and sports medicine meetings, and extensive studies supporting the Cerora MindReader biosensor device and software have now been presented in scientific sessions and one peer reviewed publication.
About Cerora’s Technologies
The rapid diagnosis of brain disease and injuries can lead to early and effective intervention with resulting cost savings, improved clinical outcomes, and increased patient satisfaction for people with concussions/traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, and other neurologic and psychiatric conditions. There are currently no affordable, portable, and accurate neuro-diagnostics available to physicians, nurses, first responders, and trainers for use in real time.
About Cerora, Inc.
Cerora is leading the way in the development and testing of software and hardware technologies required to provide critically important, objective, portable biomarker-based brain function diagnostic information. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania’s Tech Ventures on Lehigh University’s Mountaintop Campus in Bethlehem, Pennsylvania, the company has assembled a team of experienced medical scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.
For additional information, please visit www.cerora.com .
Follow us on twitter: @CeroraInc .
Investor Relations Contact: